NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
நேரலைசமீபத்திய அறிவிப்பு: 2026-10-26 19:21இன்று 0 பகுப்பாய்வு செய்யப்பட்டது
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Astec LifeSciences Reports Q2 FY27 Net Loss Widens to ₹37.4 Cr; Revenue Down 3% to ₹72.6 Cr
Astec LifeSciences reported a continuing stretch of operational losses for Q2 FY27, with net loss widening to ₹37.4 crore compared to a loss of ₹24.4 crore in Q2 FY26. Total income declined 3% YoY to ₹72.6 crore, driven by pricing pressures and channel destocking in export markets, where revenue dropped 30% YoY to ₹28.9 crore. Consolidated EBITDA slipped deeper into the red at negative ₹19.2 crore versus negative ₹5.6 crore last year, impacted by lower realizations and a ₹3 crore inventory write-down. On a positive note, CDMO segment revenue grew 15% YoY to ₹15 crore.
உச்சம் நம்பிக்கை
என்ன மாறியதுAstec reported its Q2 and H1 FY27 results, showing widening operational and net losses due to persistent agrochemical industry headwinds.
ஏன் இது முக்கியம்Astec's prolonged negative EBITDA and TTM net losses continue to strain operating cash flows and balance sheet leverage (D/E around 0.99x).
Q2 FY27 Total Income: ₹72.6 கோடிQ2 FY27 EBITDA: (₹19.2 cr)Q2 FY27 Net Loss: (₹37.4 cr)H1 FY27 Net Loss: (₹56.1 cr)Inventory write-down: ₹3 கோடி
📅 குறுகிய காலம்Weak operating results and widening EBITDA losses are likely to keep market sentiment muted in the near term.
📈 நீண்ட காலம்Recovery hinges on global destocking coming to an end, stabilization of Chinese enterprise pricing, and scaling the higher-margin CDMO business.
⚠ அபாய எச்சரிக்கைகள்
Continued negative operating margins and widening losses
Global channel destocking and Chinese oversupply suppressing realisations
High debt levels relative to net worth (D/E at 0.99x)
👀 கவனிக்க வேண்டியவை
Track the pace of channel destocking and Chinese supply dynamics over upcoming quarters, along with CDMO segment ramp-up to see when operating EBITDA turns positive.
₹0.1 Cr EBITDA Breakeven: Astec LifeSciences Narrows Q1 Loss to ₹18.7 Cr
Astec LifeSciences reported a narrowed consolidated net loss of ₹18.7 crore for Q1 FY27, compared to a loss of ₹33.0 crore in Q1 FY26. While total income declined 8% YoY to ₹84.3 crore, the company achieved an EBITDA breakeven of ₹0.1 crore, reversing a ₹10.5 crore operating loss from the previous year. The Enterprise segment showed strength with 41.6% revenue growth, but the CDMO segment faced a sharp 41.8% decline due to a high base effect.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has transitioned from an operating loss to EBITDA breakeven despite a decline in total revenue, indicating improved product mix and capacity utilization.
ஏன் இது முக்கியம்After several quarters of significant losses and negative OPM, reaching EBITDA breakeven is a critical first step toward financial recovery for this Godrej Group company, especially given its high debt-to-equity ratio of 1.15.
Q1 FY27 Total Income: ₹84.3 கோடிQ1 FY27 EBITDA: ₹0.1 கோடிQ1 FY27 Net Loss: ₹18.7 கோடிEnterprise Revenue Growth: 41.6%CDMO Revenue Decline: 41.8%Q1 வருவாய் vs TTM வருவாய்: 18.8%
📅 குறுகிய காலம்The narrowing of losses and EBITDA breakeven may provide some relief to the stock price, though the overall net loss remains substantial.
📈 நீண்ட காலம்Structural recovery depends on the agrochemical industry's demand-supply balance evening out and the company successfully shifting its mix toward the higher-margin CDMO segment.
⚠ அபாய எச்சரிக்கைகள்
Continued net losses
High debt-to-equity ratio (1.15)
Significant volatility in CDMO segment revenues
Global agrochemical demand-supply imbalance
👀 கவனிக்க வேண்டியவை
Investors should monitor the sustainability of the EBITDA breakeven and the recovery of the CDMO segment, which is critical for the company's long-term margin expansion strategy.
Rs 18.7 Cr Net Loss in Q1 FY27; Revenue declines 47% QoQ to Rs 83.6 Cr
Astec LifeSciences reported a consolidated net loss of Rs 18.71 Cr for the quarter ended June 30, 2026, narrowing from a Rs 33.03 Cr loss in the same quarter last year. However, performance deteriorated sequentially as revenue from operations fell 47.3% from Rs 158.62 Cr in Q4 FY26 to Rs 83.56 Cr. The company continues to struggle with profitability, posting a negative operating margin of -0.80% and a negative net profit margin of -22.39%. Debt levels remain a concern with a debt-to-equity ratio of 0.98 and an interest service coverage ratio of just 0.03.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company reported its Q1 FY27 results, showing a significant sequential revenue drop and continued net losses, though the loss magnitude decreased compared to the previous year's first quarter.
ஏன் இது முக்கியம்The continued losses and negative margins highlight the ongoing impact of global destocking and Chinese oversupply on the agrochemical sector, testing the company's financial resilience given its high debt-to-equity ratio.
Revenue from Operations (Q1 FY27): Rs 83.56 கோடிNet Loss (Q1 FY27): Rs 18.71 கோடிQoQ Revenue Growth: -47.3%Operating Margin: -0.80%Debt-to-Equity Ratio: 0.98Interest Service Coverage Ratio: 0.03
📅 குறுகிய காலம்The stock may face downward pressure due to the sharp sequential decline in revenue and the persistence of net losses.
📈 நீண்ட காலம்Structural recovery depends on the successful transition to a CDMO-heavy model and the stabilization of global pesticide prices; until then, the high debt remains a structural risk.
⚠ அபாய எச்சரிக்கைகள்
Continued net losses
Negative operating margins
High debt-to-equity ratio (0.98)
Critically low interest coverage (0.03)
👀 கவனிக்க வேண்டியவை
Investors should monitor the company's ability to ramp up its CDMO segment and improve capacity utilization at the Rabale R&D center to offset pricing pressures in the enterprise segment.
Astec LifeSciences Shareholders Approve New Directors and FY27 Related Party Transactions
Astec LifeSciences has received shareholder approval via postal ballot for the appointment of five directors, including Mr. Arijit Mukherjee as Executive Director and Mr. Burjis N. Godrej as Non-Executive Director. Crucially, shareholders approved material Related Party Transactions (RPTs) with Godrej Agrovet and Godrej Industries for FY 2026-27. Notably, 77.90% of institutional investors voted against the RPT resolutions, which passed only due to support from non-institutional public shareholders (99.69% in favor). The company continues to face financial headwinds with a TTM net loss of ₹81 crore.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has formalized its board structure with new appointments and secured legal clearance to conduct material business transactions with its holding companies for the 2026-27 fiscal year.
ஏன் இது முக்கியம்Ensures operational continuity within the Godrej ecosystem, which is critical as the company attempts to pivot toward higher-margin CDMO services to offset current operating losses and a high Debt/Equity ratio of 1.15.
Institutional Dissent on RPTs: 77.90%Public Votes in Favor of RPTs: 52.86%TTM Net Profit: ₹-81 crPromoter Holding: 71.97%Debt-to-Equity Ratio: 1.15
📅 குறுகிய காலம்The stock is likely to remain neutral in the short term as these approvals were expected, though the institutional pushback may be noted by governance-focused investors.
📈 நீண்ட காலம்The leadership of the new Executive Director will be judged by the company's ability to utilize its new R&D center and herbicide facility to return to profitability.
⚠ அபாய எச்சரிக்கைகள்
High institutional dissent on Related Party Transactions
Significant TTM losses
High debt levels relative to net worth
👀 கவனிக்க வேண்டியவை
Investors should monitor the specific value and terms of Related Party Transactions in upcoming quarterly reports, given the high level of institutional skepticism regarding these dealings with the parent group.
Astec LifeSciences shareholders have approved seven resolutions via postal ballot, including the appointment of Arijit Mukherjee as Executive Director and COO. While all management appointments passed with over 99% support, Related Party Transactions (RPT) with Godrej Agrovet and Godrej Industries for FY 2026-27 faced significant resistance. Specifically, 77.9% of institutional votes were cast against these RPT resolutions, which ultimately passed with a narrow 52.86% majority of polled votes as promoters were restricted from voting. This comes as the company struggles with a TTM PAT of Rs -81 Cr and negative OPM.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has formalized its leadership structure with a new Executive Director/COO and secured legal approval for material transactions with its parent Godrej Group for the 2026-27 fiscal year.
ஏன் இது முக்கியம்While management continuity is positive, the high level of institutional dissent on Related Party Transactions suggests a lack of confidence in the terms of engagement with the parent company, which is critical given Astec's current financial stress.
Institutional Dissent on RPT: 77.9%Overall RPT Approval Rate: 52.86%Management Appointment Approval: 99.99%Votes Polled vs Total Capital (RPT): 5.03%
📅 குறுகிய காலம்The passing of resolutions ensures operational continuity; however, the institutional pushback may lead to increased scrutiny of the company's governance in the coming weeks.
📈 நீண்ட காலம்The appointment of a COO is a structural step toward executing the CDMO growth strategy, but the company must address its high debt-to-equity ratio (1.15) and loss-making operations to regain institutional trust.
⚠ அபாய எச்சரிக்கைகள்
High institutional dissent on Related Party Transactions
Negative operating margins (-1.0%)
High Debt-to-Equity ratio of 1.15
👀 கவனிக்க வேண்டியவை
Monitor the scale and pricing of transactions with Godrej Agrovet in upcoming quarterly reports to evaluate if institutional concerns regarding RPT terms are justified, especially given the current negative ROCE of -5.0%.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Astec LifeSciences Seeks Shareholder Approval for Appointment of Three Directors
Astec LifeSciences has issued a postal ballot notice to seek shareholder approval for the regularization of three directors: Mr. Vishal Sharma, Mr. Burjis N. Godrej, and Mr. Arijit Mukherjee. These individuals were previously appointed as Additional Directors by the Board effective April 13, 2026. The e-voting period for these resolutions is scheduled from June 5, 2026, to July 4, 2026. This is a standard regulatory procedure to confirm board appointments made during the interim period.
முக்கிய அம்சங்கள்
Shareholder approval sought for the appointment of Vishal Sharma, Burjis N. Godrej, and Arijit Mukherjee as Directors.All three directors were initially appointed as Additional Directors effective April 13, 2026.The e-voting window is open for 30 days, from June 5, 2026, to 5:00 p.m. IST on July 4, 2026.The cut-off date for determining shareholder eligibility to vote was May 29, 2026.Voting results will be declared within two working days after the close of the voting period on July 4, 2026.
👀 கவனிக்க வேண்டியவை
Investors should review the qualifications of the proposed directors and exercise their voting rights through the NSDL e-voting platform before the July 4 deadline.
Astec LifeSciences Approves FY26 Audited Results and Proposes New Board Appointments
Astec LifeSciences has approved its audited standalone and consolidated financial results for the fiscal year ended March 31, 2026, reporting a net loss for the period. The company has scheduled its 32nd Annual General Meeting for July 31, 2026, with a book closure period from July 26 to July 30, 2026. A postal ballot is being initiated to seek shareholder approval for the appointment of several directors, including Burjis N. Godrej and Vishal Sharma as Non-Executive Directors. Additionally, the board is seeking approval for material related party transactions for the 2026-27 financial year.
முக்கிய அம்சங்கள்
Approved audited financial results for the quarter and financial year ended March 31, 2026, with an unmodified auditor's opinion.The company reported a net loss for the financial year 2025-26 as per the statutory auditor's report.32nd Annual General Meeting (AGM) scheduled for July 31, 2026, at 4:00 p.m.Proposed appointments of Burjis N. Godrej, Vishal Sharma, Arijit Mukherjee, and Mathew Eipe to the Board.Seeking shareholder approval via postal ballot for material related party transactions for FY 2026-27.
👀 கவனிக்க வேண்டியவை
Investors should carefully review the detailed financial statements to understand the factors leading to the reported net loss. Monitor the upcoming postal ballot and AGM for insights into the company's governance and strategic direction under the proposed new board members.
Astec LifeSciences Reports FY26 Net Loss; Sets AGM and Record Date for July 2026
Astec LifeSciences has approved its audited financial results for the fiscal year ended March 31, 2026, reporting a net loss for the period. The company has scheduled its 32nd Annual General Meeting (AGM) for July 31, 2026, with a record date of July 26, 2026, for book closure purposes. Significant board changes are proposed, including the appointment of Burjis N. Godrej and Vishal Sharma as Non-Executive Directors. Additionally, the company is seeking approval for material related party transactions for the 2026-27 financial year.
முக்கிய அம்சங்கள்
Reported a net loss for the financial year ended March 31, 2026, as confirmed by the statutory auditor's report.32nd Annual General Meeting scheduled for July 31, 2026, with book closure from July 26 to July 30, 2026.Proposed appointment of Vishal Sharma and Burjis N. Godrej as Non-Executive Directors.Arijit Mukherjee to be appointed as Executive Director while continuing as Chief Operating Officer.Seeking shareholder approval for material related party transactions for FY 2026-27 via postal ballot.
👀 கவனிக்க வேண்டியவை
Investors should carefully examine the full financial statements to identify the drivers behind the reported net loss. The significant management reshuffle and related party transaction approvals warrant close monitoring of future corporate governance and strategic shifts.
Astec LifeSciences Q4 FY26: Revenue Up 34% YoY to ₹161.3 Cr; EBITDA Surges 87%
Astec LifeSciences demonstrated a strong recovery in Q4 FY26, with total income increasing 34% YoY to ₹161.3 crore. EBITDA for the quarter grew by 86.9% to ₹11.8 crore, driven by volume growth in Enterprise and CDMO segments. Although the company remains in a net loss position of ₹7.7 crore for Q4, this is a significant improvement from the ₹16.1 crore loss in Q4 FY25. For the full year FY26, the company reached EBITDA breakeven, a major milestone compared to the ₹60.6 crore EBITDA loss in FY25.
முக்கிய அம்சங்கள்
Q4 FY26 total income rose 34.0% YoY to ₹161.3 crore, driven by 37.1% growth in Enterprise volumes.EBITDA for Q4 FY26 increased by 86.9% YoY to ₹11.8 crore due to margin expansion.Full-year FY26 net loss narrowed to ₹80.9 crore from ₹134.7 crore in FY25, showing a recovery trend.Domestic revenue saw a massive 133.8% YoY growth in Q4 FY26, reaching ₹54.9 crore.The Contract Manufacturing (CDMO) segment grew 29.5% YoY to ₹89.4 crore in the final quarter.
👀 கவனிக்க வேண்டியவை
The company is showing clear signs of a turnaround with narrowing losses and achieving EBITDA breakeven for the full year. Investors should monitor the sustainability of the domestic volume surge and CDMO growth as indicators of a return to net profitability.
Astec LifeSciences Announces Major Leadership Overhaul; Nadir Godrej Retires as Chairman
Astec LifeSciences has announced a significant restructuring of its top leadership effective April 13, 2026. Mr. Nadir Godrej is retiring as Chairman, with Mr. Vishal Sharma, a 30-year veteran in specialty chemicals, appointed as the new Chairperson. Furthermore, Mr. Burjis N. Godrej has resigned as Managing Director to focus on the parent company, Godrej Agrovet, while Mr. Arijit Mukherjee has been appointed as the new Executive Director and Chief Operating Officer for a three-year term.
முக்கிய அம்சங்கள்
Mr. Nadir Godrej retires as Chairperson and Director effective April 13, 2026.Mr. Vishal Sharma appointed as Chairperson and Additional Director, bringing 30 years of experience in specialty and process chemicals.Mr. Burjis N. Godrej resigns as Managing Director but continues as a Non-Executive Director to focus on Godrej Agrovet Limited.Mr. Arijit Mukherjee appointed as Executive Director and COO for a 3-year term from April 13, 2026, to April 12, 2029.Mr. Mathew Eipe appointed as an Independent Director for a term ending June 6, 2027.
👀 கவனிக்க வேண்டியவை
Investors should monitor the transition in leadership and how the new COO and Chairperson influence the company's operational performance and strategic alignment within the Godrej Group. The move of the former MD to the parent company suggests a broader group-level talent realignment.
Astec LifeSciences Announces Major Board Reshuffle; Vishal Sharma Appointed Chairperson
Astec LifeSciences has announced a significant leadership transition effective April 13, 2026. Nadir Godrej is retiring as Chairperson, and Vishal Sharma, who has 30 years of experience in specialty chemicals, has been appointed as the new Chairperson. Additionally, Burjis N. Godrej has resigned as Managing Director to take on a broader role at parent company Godrej Agrovet, though he will remain on the board as a Non-Executive Director. The board also added Mathew Eipe as an Independent Director to strengthen governance.
முக்கிய அம்சங்கள்
Nadir Godrej retires as Chairperson and Director effective April 13, 2026Vishal Sharma appointed as Chairperson and Additional Director (Non-Executive, Non-Independent)Burjis N. Godrej resigns as Managing Director but continues as a Non-Executive DirectorMathew Eipe appointed as Independent Director for a term ending June 6, 2027Vishal Sharma brings 30 years of experience from Godrej Industries, Ecolab, and Diversey
👀 கவனிக்க வேண்டியவை
Investors should monitor the transition from family-led management to a professional Chairperson and assess if this leads to any shifts in the company's strategic direction or operational efficiency. No immediate action is required as the changes appear to be a planned succession within the Godrej Group ecosystem.
Astec LifeSciences Appoints Vishal Sharma as Chairperson; Nadir Godrej to Retire
Astec LifeSciences has announced a major leadership transition effective April 13, 2026, following the retirement of Chairperson Nadir Godrej. Mr. Vishal Sharma, currently CEO (Chemicals) at Godrej Industries with 30 years of experience, will succeed him as Chairperson. In a simultaneous move, Mr. Burjis N. Godrej is stepping down as Managing Director to focus on parent company Godrej Agrovet, while remaining on the board as a Non-Executive Director. These changes indicate a strategic shift to leverage senior group expertise for Astec's specialized chemical operations.
முக்கிய அம்சங்கள்
Mr. Nadir Godrej to retire as Chairperson and Director effective April 13, 2026.Mr. Vishal Sharma appointed as Chairperson and Additional Director, bringing 30 years of specialty chemicals experience.Mr. Burjis N. Godrej resigns as Managing Director to take a broader role at parent company Godrej Agrovet Limited.Mr. Mathew Eipe appointed as Additional Independent Director for a term ending June 6, 2027.
👀 கவனிக்க வேண்டியவை
Investors should monitor how the new leadership, particularly Vishal Sharma with his deep chemical industry expertise, influences Astec's operational turnaround and growth strategy. The transition appears to be a planned realignment within the Godrej ecosystem.
ICRA Re-affirms Astec LifeSciences Ratings; Long-Term Outlook Remains Negative
ICRA has re-affirmed the credit ratings for Astec LifeSciences Limited across its various debt instruments totaling approximately Rs. 1,068 crore. The long-term ratings for cash credit, term loans, and NCDs were maintained at [ICRA]AA- but carry a 'Negative' outlook, signaling potential pressure on the credit profile. Short-term ratings for commercial paper and non-fund based facilities were re-affirmed at the highest level of [ICRA]A1+. This indicates that while the company maintains a strong credit standing, there are underlying concerns regarding its long-term financial trajectory.
முக்கிய அம்சங்கள்
Long-term rating of [ICRA]AA- re-affirmed for Rs. 283 crore Cash Credit and Rs. 100 crore Term Loan with a Negative outlook.Short-term rating of [ICRA]A1+ maintained for Rs. 300 crore Commercial Paper and Rs. 335 crore non-fund based facilities.Rs. 50 crore Non-Convertible Debenture (NCD) programme re-affirmed at [ICRA]AA- with a Negative outlook.Total debt facilities reviewed by ICRA across three separate rating letters amount to Rs. 1,068 crore.The 'Negative' outlook suggests ICRA is monitoring risks that could lead to a rating downgrade in the future.
👀 கவனிக்க வேண்டியவை
Investors should remain cautious due to the 'Negative' outlook on long-term debt, which suggests potential credit quality deterioration. It is advisable to monitor the company's upcoming quarterly earnings for signs of operational recovery and debt reduction.
Astec LifeSciences Q3FY26: Revenue Up 31% YoY, Returns to Positive EBITDA of Rs 4.8 Cr
Astec LifeSciences reported a significant recovery in Q3FY26, with total income rising 31% YoY to Rs 125.5 crore. The company achieved a positive EBITDA of Rs 4.8 crore, a notable turnaround from the Rs 3.8 crore loss in the same quarter last year. While the company still reported a net loss of Rs 15.7 crore, it is a substantial reduction from the Rs 40.4 crore loss in Q3FY25. Growth was primarily driven by higher enterprise volumes and improved offtake in the Contract Development and Manufacturing Organization (CDMO) segment.
முக்கிய அம்சங்கள்
Total income grew 31% YoY to Rs 125.5 crore in Q3FY26 compared to Rs 95.8 crore in Q3FY25.EBITDA turned positive at Rs 4.8 crore in Q3FY26 versus a loss of Rs 3.8 crore in the previous year.Net loss narrowed significantly to Rs 15.7 crore from a loss of Rs 40.4 crore in the same period last year.Enterprise segment revenue increased by 36.7% YoY, while Contract Manufacturing grew by 29.7% YoY.Domestic sales witnessed a sharp growth of 55.9% YoY, reaching Rs 37.9 crore.
👀 கவனிக்க வேண்டியவை
The return to positive EBITDA and narrowing losses suggest a recovery phase; investors should monitor the sustainability of CDMO volumes and margin improvement in upcoming quarters.
Astec LifeSciences Q3 Net Loss Narrows to ₹15.7 Cr; Revenue Up 33% YoY
Astec LifeSciences reported a significant narrowing of its net loss to ₹15.72 crore in Q3 FY26, compared to a ₹40.40 crore loss in the same period last year. Revenue from operations grew by 32.9% year-on-year to ₹124.72 crore, showing signs of operational recovery. The company also announced a leadership transition, with CFO Mugdha Amol Khare resigning and Deepak Jawaharlal Ochani, a Godrej Agrovet veteran, appointed as the new CFO effective April 2026. The balance sheet has strengthened, with the debt-equity ratio improving to 1.08 from 2.06 a year ago.
முக்கிய அம்சங்கள்
Revenue from operations increased 32.9% YoY to ₹124.72 crore in Q3 FY26.Net loss narrowed to ₹15.72 crore from ₹40.40 crore in the previous year's corresponding quarter.Debt-to-Equity ratio improved significantly to 1.08 compared to 2.06 in December 2024.Exceptional item of ₹2.09 crore recognized due to the financial impact of new Government Labour Codes.CFO transition: Deepak Ochani to succeed Mugdha Khare effective April 1, 2026.
👀 கவனிக்க வேண்டியவை
Investors should monitor if the narrowing losses and revenue growth translate into a full turnaround in the coming quarters. The appointment of a Godrej group veteran as CFO suggests a focus on financial stability, but the company remains in a loss-making position.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
